Percutaneous Treatment of Protected and Unprotected Left Main Coronary Stenoses With New Devices: Immediate Angiographic Results and Intermediate-Term Follow-Up

Objectives. We sought to evaluate the immediate angiographic results and intermediate-term follow-up after percutaneous treatment of left main coronary stenoses in the new device era. Background. Historically, balloon angioplasty of left main coronary stenoses has been associated with high procedural morbidity and poor long-term results. It is not clear whether new devices are more effective in this anatomic setting. Methods. Between July 1993 and July 1995, we performed initial left main coronary interventions on 46 patients (mean age 67 ± 12 years, 26% women). Quantitative angiography was available for 42 of 46 interventions, and clinical follow-up was obtained for all patients at 1 month, 6 months and 1 year after initial revascularization. Results. Most interventions (42 of 46) were performed in patients with “protected” coronary stenoses to the left coronary system owing to the presence of one or more patent left main coronary grafts. Seventy-seven percent of screened patients were deemed unsuitable for repeat coronary artery bypass surgery. Procedures performed included stenting in 73% of patients (alone in 30% and after rotational atherectomy in 43%), rotational atherectomy in 58% (alone in 15% and before stenting in 43%), directional atherectomy in 4% and angioplasty alone in 7%. Initial procedural success was achieved in all interventions, with no deaths, myocardial infarctions (creatine kinase, MB fraction>50 IU/liter) or emergent bypass surgery. Follow-up dat to date (median duration 9 months, range 6 to 19) demonstrate 98% overall survival rate and 6-month event-free survival rate of 78% (six target vessel revascularizations [TVRs], four non-TVRs). Conclusions. Treatment of protected left main coronary artery stenoses can be accomplished safely and effectively with new device technology. Intermediate-term follow-up demonstrates an acceptably low rate of death, myocardial infarction or repeat revascularization at 6 months and 1 year.